Abstracts tagged "Patient reported outcomes"

Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Isabel Castrejón Fernández¹, Lucia Otero², Antonio Mera-Valera³, Alicia Garcia⁴, Silvia Gomez-Sabater⁵, Raquel Martín-Domenech⁶, Jose Alvaro-Gracia⁷, Juan Camilo Sarmiento-Monroy⁸, Beatriz Ventosa² and Fernando Sánchez-Alonso⁹, ¹Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³H. Clínico Universitario de Santiago, Santiago de Compostela, ⁴Rheumatologist, La Laguna, Spain, ⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁶H. Universitario de Elda, Elda, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Rosa Maria Morlà Novell¹, Enrique González-Dávila², Beatriz Frade Sosa³, Maria López-Lasanta⁴, Noemí Busquets Pérez⁵, Marta Valls Roc⁶, Meritxell Sallés Lizarzáburu⁷, Georgina Salvador Alarcón⁸, Virginia Ruiz-Esquide⁹, Lola Tobalina Mastre¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Dr Trueta, Girona, Sudan, ⁷Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
Abstract Number: 0564 • ACR Convergence 2025
Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alice Gottlieb¹, Joseph F Merola², Philip J. Mease³, Christopher Ritchlin⁴, Jose U. Scher⁵, Kimberly Parnell Lafferty⁶, Daphne Chan⁷, Soumya Chakravarty⁸, Wayne Langholff⁹, Yanli Wang⁹, Olivia Choi, MD, PhD, FAAD⁷, Yevgeniy Krol¹⁰ and Alexis Ogdie¹¹, ¹Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johnson & Johnson, Dermatology, Horsham, PA, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Johnson & Johnson, Biostatistics, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, ¹¹University of Pennsylvania School of Medicine, Philadelphia, PA
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated efficacy in significantly improving psoriatic arthritis (PsA) signs and symptoms in participants (pts) with active…
Abstract Number: 1266 • ACR Convergence 2025
Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
Jennifer Barton¹, Joshua Baker², gabriela Schmajuk³, Madhavi Valiveti⁴, Alexandra Bennett⁵, Benjamin Morasco⁶, Allison O'Neill⁷ and Meike Niederhausen⁸, ¹VA Portland Health Care System/OHSU, Portland, OR, ²University of Pennsylvania, Philadelphia, PA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴VAMC Wilmington, Wilmington, DE, ⁵Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ⁶Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁷Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁸Oregon Health & Science University/VA Portland Health Care System, Portland, OR
Background/Purpose: Shared decision making (SDM) is outlined as the first overarching principle of the treat to target guidelines for rheumatoid arthritis (RA). The quality of…
Abstract Number: 1558 • ACR Convergence 2025
Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study
Thomas Guedens¹, Elvira Lesmana², Adam Edwinson³, Margaret Breen-Lyles¹, Anukul Karn⁴, Madhusudan Grover¹ and Ashima Makol³, ¹Mayo Clinic, Rochester, Rochester, MN, ²Mayo Clinic, Rochester, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Trinity Health Livonia, Farmington Hills, MI
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem auto-immune disease characterized by peripheral vasculopathy and widespread fibrosis of the skin and internal organs. Up to…
Abstract Number: 2144 • ACR Convergence 2025
The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira¹, Cristina Burroughs³, Katrina Bargender⁴, Amy Bolton⁴, Christine Yeung⁴, Jennifer Gordon⁵, Peter Merkel⁶ and Karen James⁷, ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, ³University of South Florida, Tampa, FL, ⁴Vasculitis Patient-Powered Research Network, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT
Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on…
Abstract Number: 2564 • ACR Convergence 2025
An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
Mie Fusama¹, Hideko Nakahara², Megumi Okada³, Kayoko Sakagami⁴, Ikuyo Noguchi⁵, Harumi Matsumura⁶, Hiroaki Ito⁴, Kosaku Oda⁵, Yoshitaka Shinto³, Kenshi Higami⁶, Satomi Higami⁶ and Tetsuya Tomita⁷, ¹Kansai University of International Studies, Miki, Japan, ²Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, ³Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, ⁴Infusion Clinic, Osaka, Japan, ⁵Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, ⁶Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, ⁷Morinomiya University of Medical Sciences, Osaka, Japan
Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Rosa Maria Morlà Novell¹, Beatriz Frade Sosa², Maria López-Lasanta³, Meritxell Sallés Lizarzáburu⁴, Noemí Busquets Pérez⁵, Georgina Salvador Alarcón⁶, Marta Valls Roc⁷, Virginia Ruiz-Esquide⁸, Lola Tobalina Mastre⁹, Raimon Sanmartí⁸ and José Gomez-Puerta¹⁰, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁴Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁷Hospital Universitari Dr Trueta, Girona, Sudan, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
Abstract Number: 0573 • ACR Convergence 2025
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Joseph F Merola¹, Alexis Ogdie², Alice B. Gottlieb³, Fabian Proft⁴, Nuala Brennan⁵, Alex Godwood⁵, Matthew R. Thomas⁵, Eva Cullen⁵, Kristian Reich⁶, Laura Coates⁷ and Laure Gossec⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵MoonLake Immunotherapeutics AG, Zug, Switzerland, ⁶MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 1566 • ACR Convergence 2025
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Peter Merkel³, Alisa Stephens Shields³, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Sonali Bracken⁷, Flavia Castelino⁸, Lorinda Chung⁹, Luke Evnin¹⁰, Tracy Frech¹¹, Jessica Gordon¹², Faye Hant¹³, Monica Harding¹⁴, Laura Hummers¹⁵, Dinesh Khanna¹⁶, Kimberly Lakin¹², Dorota Lebiedz-Odrobina¹⁴, Yiming Luo⁶, Ashima Makol¹⁷, Maureen Mayes¹⁸, Zsuzsanna McMahan¹⁹, Jerry Molitor²⁰, Duncan Moore²¹, Carrie Richardson²², Ami Shah¹⁵, Ankoor Shah²³, Brian Skaug²⁴, Virginia Steen²⁵, John VanBuren¹⁴, Elizabeth Volkmann²⁶, Carleigh Zahn¹⁶ and Nora Sandorfi³, ¹University of Pennsylvania, Media, PA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ³University of Pennsylvania, Philadelphia, PA, ⁴Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶Columbia University, New York, NY, ⁷Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁸Massachusetts General Hospital, Boston, MA, ⁹Stanford University, Stanford, CA, ¹⁰Scleroderma Research Foundation, San Francisco, CA, ¹¹Vanderbilt University Medical Center, Nashville, TN, ¹²Hospital for Special Surgery, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸UT Health Houston Division of Rheumatology, Houston, TX, ¹⁹UT Health Houston, Houston, TX, ²⁰University of Minnesota, Minneapolis, MN, ²¹Northwestern Memorial Hospital, Chicago, IL, ²²Northwestern University, Chicago, IL, ²³Duke University, Durham, NC, ²⁴UTHealth Houston Division of Rheumatology, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
Abstract Number: 2234 • ACR Convergence 2025
Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Cheuk Yin Tam, Ho So and Lai Shan Tam, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: This study compared the impact of achieving early sustained remission (sREM) versus early sustained low disease activity (sLDA) on patient-reported outcomes (PROs) after 5…
Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Madison Negron¹, Jiaqi Wang², Xiaosong Wang³, Lauren O'Keeffe⁴, Grace Qian⁴, Kevin Mueller⁴, Alene Saavedra⁴, Natalie Davis⁵, Liya Sisay Getachew⁶, Jeffrey Sparks⁶ and Naomi Patel⁷, ¹Harvard Extension School, Medford, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…

« Previous Page
1
…
5
6
7
8
9
…
50
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].